| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
ORIGINAL RESEARCH |
From the Division of Gynecologic Oncology, Walter Reed Army Medical Center, Washington, District of Columbia; and Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, North Carolina.
Address reprint requests to: Evan R. Myers, MD, MPH, Duke University Medical Center, Department of Obstetrics and Gynecology, Durham, NC 27710.
OBJECTIVE: To estimate the potential effects, on costs and outcomes, of changes in sensitivity and specificity associated with new screening methods for cervical cancer in the military.
METHODS: A Markov model of the natural history of cervical cancer was created to simulate a cohort of 100,000 military beneficiaries aged 18–85. Probability estimates for various outcomes and the accuracy of screening tests were obtained from the literature. Cost estimates were obtained from military sources where available; otherwise, civilian costs were used. The outcomes and costs of conventional cytology, liquid-based cytology, and liquid-based cytology with human papillomavirus (HPV) triage were compared at 1-, 2-, and 3-year screening frequencies.
RESULTS: Marginal reductions in the incidence of cervical cancer from increasing screening sensitivity are greater than reductions in cancer mortality at every screening interval. Incremental improvements in both cancer incidence and mortality are higher at less frequent screening intervals. Increases in the ratio of low- to high-grade lesions result from increasing the sensitivity of the screening test or shortening the screening interval. Both liquid-based cytology and liquid-based cytology with HPV testing are cost effective (less than $50,000 per life-year saved) when performed at 3-year screening intervals. However, neither strategy is cost-effective when performed more frequently than every 3 years.
CONCLUSION: Use of a more sensitive cervical cancer screening test increases costs. However, a more sensitive test performed less frequently may be more effective and less expensive than conventional cytology done annually. In the military setting, this has significant implications for both expense reduction and readiness enhancement.
This article has been cited by other articles:
|
|
 |
|
  M. A. Bidus, G. L. Maxwell, S. Kulasingam, G. S. Rose, J. C. Elkas, M. Chernofsky, and E. R. Myers Cost-effectiveness analysis of liquid-based cytology and human papillomavirus testing in cervical cancer screening. Obstet. Gynecol., May 1, 2006; 107(5): 997 - 1005. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 U. Siebert, G. Sroczynski, P. Hillemanns, J. Engel, R. Stabenow, C. Stegmaier, K. Voigt, B. Gibis, D. Holzel, and S. J. Goldie The German Cervical Cancer Screening Model: development and validation of a decision-analytic model for cervical cancer screening in Germany Eur J Public Health, April 1, 2006; 16(2): 185 - 192. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Melnikow and S. Birch Human Papillomavirus Triage of Atypical Squamous Cells of Undetermined Significance: Cost-Effective, But At What Cost? J Natl Cancer Inst, January 18, 2006; 98(2): 82 - 83. [Full Text] [PDF]
|
|
|
|
|
|
S. L. Kulasingam, J. J. Kim, W. F. Lawrence, J. S. Mandelblatt, E. R. Myers, M. Schiffman, D. Solomon, and S. J. Goldie Cost-Effectiveness Analysis Based on the Atypical Squamous Cells of Undetermined Significance/Low-Grade Squamous Intraepithelial Lesion Triage Study (ALTS) J Natl Cancer Inst, January 18, 2006; 98(2): 92 - 100. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. F. Sawaya A 21-Year-Old Woman With Atypical Squamous Cells of Undetermined Significance JAMA, November 2, 2005; 294(17): 2210 - 2218. [Full Text] [PDF]
|
|
|
|
|
|
S. L. Kulasingam and E. R. Myers Potential Health and Economic Impact of Adding a Human Papillomavirus Vaccine to Screening Programs JAMA, August 13, 2003; 290(6): 781 - 789. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
